Free Trial
→ Now I look stupid. Real stupid... (From Porter & Company) (Ad) Buy RKLIF Stock  Free RKLIF Stock Alerts

Rentokil Initial (RKLIF) Financials

Rentokil Initial logo
$4.40 0.00 (0.00%)
As of 04/23/2025
Compare
Annual Income Statements for Rentokil Initial

Annual Income Statements for Rentokil Initial

This table shows Rentokil Initial's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 254 355 280 486 384
Consolidated Net Income / (Loss)		 254 355 280 486 384
Net Income / (Loss) Continuing Operations		 254 355 280 486 384
Total Pre-Tax Income 		314 439 357 628 507
Total Operating Income		 402 468 383 796 687
Total Gross Profit		 402 468 412 846 758
Total Revenue		 3,828 3,992 4,485 6,849 6,806
Operating Revenue		 3,828 3,992 4,485 6,849 6,806
Total Cost of Revenue		 3,427 3,524 4,074 6,003 6,049
Operating Cost of Revenue		 3,427 3,524 4,074 6,003 6,049
Total Operating Expenses		 0.00 0.00 29 50 70
Impairment Charge		 0.00 0.00 29 50 70
Total Other Income / (Expense), net		 -87 -30 -25 -168 -180
Interest Expense		 107 46 95 241 247
Interest & Investment Income		 8.19 5.40 59 61 58
Other Income / (Expense), net		 11 11 11 11 8.76
Income Tax Expense		 60 84 77 143 123
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 92 -16 356 287 -56
Basic Earnings per Share		 $0.10 $0.14 $0.14 $0.19 $0.15
Weighted Average Basic Shares Outstanding		 - - 2.52B 2.52B 2.52B
Diluted Earnings per Share		 $0.10 $0.14 $0.14 $0.19 $0.15
Weighted Average Diluted Shares Outstanding		 - - 2.52B 2.52B 2.52B
Weighted Average Basic & Diluted Shares Outstanding		 - - 2.52B 2.52B 2.52B

Quarterly Income Statements for Rentokil Initial

No quarterly income statements for Rentokil Initial are available.

Annual Cash Flow Statements for Rentokil Initial

This table details how cash moves in and out of Rentokil Initial's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 382 -398 -827 54 177
Net Cash From Operating Activities		 478 437 402 362 392
Net Cash From Continuing Operating Activities		 478 437 402 362 392
Net Income / (Loss) Continuing Operations		 0.00 0.00 0.00 0.00 0.00
Depreciation Expense		 - 278 307 349 353
Non-Cash Adjustments To Reconcile Net Income		 478 123 95 13 39
Net Cash From Investing Activities		 -434 -616 -1,229 -308 -215
Net Cash From Continuing Investing Activities		 -434 -616 -1,229 -308 -215
Acquisitions		 -265 -625 -1,229 -308 -215
Net Cash From Financing Activities		 462 -225 0.00 0.00 0.00
Net Cash From Continuing Financing Activities		 462 -225 0.00 0.00 0.00
Cash Interest Received		 11 6.75 16 32 45

Quarterly Cash Flow Statements for Rentokil Initial

No quarterly cash flow statements for Rentokil Initial are available.

Annual Balance Sheets for Rentokil Initial

This table presents Rentokil Initial's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Total Assets		 5,736 14,163 13,894 12,917
Total Current Assets		 1,814 3,909 3,437 2,613
Cash & Equivalents		 902 2,621 1,990 1,158
Short-Term Investments		 5.40 1.21 19 2.50
Accounts Receivable		 711 1,002 1,121 1,138
Inventories, net		 184 242 264 287
Current Deferred & Refundable Income Taxes		 12 43 42 28
Plant, Property, & Equipment, net		 537 598 636 629
Plant, Property & Equipment, gross		 537 598 636 629
Total Noncurrent Assets		 3,384 9,656 9,821 9,675
Long-Term Investments		 41 104 83 73
Intangible Assets		 2,921 8,820 8,974 8,900
Noncurrent Deferred & Refundable Income Taxes		 57 52 55 43
Other Noncurrent Operating Assets		 366 680 710 660
Total Liabilities & Shareholders' Equity		 5,837 14,422 14,179 13,215
Total Liabilities		 4,131 9,473 8,970 7,921
Total Current Liabilities		 1,877 3,429 3,286 3,224
Short-Term Debt		 620 1,624 1,445 1,460
Accounts Payable		 1,031 1,408 1,458 1,400
Current Deferred & Payable Income Tax Liabilities		 82 72 61 54
Other Current Liabilities		 143 324 322 311
Total Noncurrent Liabilities		 2,255 6,045 5,683 4,697
Long-Term Debt		 1,696 4,316 4,018 3,128
Capital Lease Obligations		 188 393 405 394
Noncurrent Deferred & Payable Income Tax Liabilities		 146 620 659 640
Noncurrent Employee Benefit Liabilities		 36 36 36 31
Other Noncurrent Operating Liabilities		 189 680 566 503
Total Equity & Noncontrolling Interests		 1,706 4,949 5,209 5,294
Total Preferred & Common Equity		 1,708 4,950 5,211 5,295
Preferred Stock		 9.45 11 18 19
Total Common Equity		 1,698 4,939 5,193 5,276
Common Stock		 26 30 32 31
Retained Earnings		 4,274 3,988 4,483 4,515
Other Equity Adjustments		 -2,601 921 678 730
Noncontrolling Interest		 -1.35 -1.21 -1.27 -1.25

Quarterly Balance Sheets for Rentokil Initial

No quarterly balance sheets for Rentokil Initial are available.

Annual Metrics and Ratios for Rentokil Initial

This table displays calculated financial ratios and metrics derived from Rentokil Initial's official financial filings.

Metric 2020 2021 2022 2023 2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 4.28% 12.36% 52.70% -0.63%
EBITDA Growth		 0.00% 83.62% -7.51% 65.18% -9.32%
EBIT Growth		 0.00% 16.20% -17.85% 105.20% -13.83%
NOPAT Growth		 0.00% 16.75% -20.84% 105.12% -15.34%
Net Income Growth		 0.00% 39.77% -21.09% 73.28% -20.83%
EPS Growth		 0.00% 41.28% -1.42% 38.13% -20.83%
Operating Cash Flow Growth		 0.00% -8.49% -8.06% -10.01% 8.29%
Free Cash Flow Firm Growth		 0.00% 0.00% -73.90% 104.40% 123.75%
Invested Capital Growth		 0.00% 0.00% 162.53% 4.85% 0.52%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - -
Gross Margin		 10.49% 11.73% 9.18% 12.35% 11.13%
EBITDA Margin		 10.77% 18.97% 15.62% 16.89% 15.42%
Operating Margin		 10.49% 11.73% 8.54% 11.63% 10.10%
EBIT Margin		 10.77% 12.01% 8.78% 11.80% 10.23%
Profit (Net Income) Margin		 6.64% 8.89% 6.25% 7.09% 5.65%
Tax Burden Percent		 80.87% 80.92% 78.38% 77.28% 75.80%
Interest Burden Percent		 76.16% 91.55% 90.80% 77.76% 72.84%
Effective Tax Rate		 19.13% 19.08% 21.62% 22.72% 24.20%
Return on Invested Capital (ROIC)		 0.00% 23.99% 5.24% 7.24% 5.97%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 20.68% 4.41% 3.44% 2.04%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 17.62% 3.18% 2.32% 1.35%
Return on Equity (ROE)		 0.00% 41.61% 8.42% 9.56% 7.32%
Cash Return on Invested Capital (CROIC)		 0.00% -176.01% -84.43% 2.50% 5.46%
Operating Return on Assets (OROA)		 0.00% 8.35% 3.96% 5.76% 5.19%
Return on Assets (ROA)		 0.00% 6.19% 2.82% 3.46% 2.87%
Return on Common Equity (ROCE)		 0.00% 41.42% 8.40% 9.53% 7.30%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 20.79% 5.66% 9.32% 7.26%
Net Operating Profit after Tax (NOPAT)		 325 379 300 616 521
NOPAT Margin		 8.48% 9.50% 6.69% 8.99% 7.66%
Net Nonoperating Expense Percent (NNEP)		 0.00% 3.31% 0.83% 3.80% 3.94%
Return On Investment Capital (ROIC_SIMPLE)		 - - 2.66% 5.56% 5.07%
Cost of Revenue to Revenue		 89.51% 88.27% 90.82% 87.65% 88.87%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.65% 0.73% 1.03%
Earnings before Interest and Taxes (EBIT)		 412 479 394 808 696
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 412 757 700 1,157 1,049
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 2.72 2.42
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 2.07 1.88
Price to Earnings (P/E)		 0.00 0.00 0.00 29.13 33.23
Dividend Yield		 0.00% 0.00% 0.00% 1.77% 2.28%
Earnings Yield		 0.00% 0.00% 0.00% 3.43% 3.01%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 2.06 1.89
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 2.62 2.43
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 15.50 15.76
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 22.20 23.76
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 29.14 31.74
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 49.56 42.21
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 84.31 34.75
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 1.47 1.28 1.13 0.94
Long-Term Debt to Equity		 0.00 1.10 0.95 0.85 0.67
Financial Leverage		 0.00 0.85 0.72 0.67 0.66
Leverage Ratio		 0.00 3.36 2.99 2.76 2.55
Compound Leverage Factor		 0.00 3.08 2.71 2.15 1.86
Debt to Total Capital		 0.00% 59.46% 56.13% 52.97% 48.48%
Short-Term Debt to Total Capital		 0.00% 14.72% 14.40% 13.05% 14.21%
Long-Term Debt to Total Capital		 0.00% 44.74% 41.74% 39.93% 34.28%
Preferred Equity to Total Capital		 0.00% 0.22% 0.10% 0.16% 0.18%
Noncontrolling Interests to Total Capital		 0.00% -0.03% -0.01% -0.01% -0.01%
Common Equity to Total Capital		 0.00% 40.35% 43.78% 46.88% 51.35%
Debt to EBITDA		 0.00 3.30 9.04 5.07 4.75
Net Debt to EBITDA		 0.00 2.05 5.15 3.26 3.57
Long-Term Debt to EBITDA		 0.00 2.49 6.72 3.82 3.36
Debt to NOPAT		 0.00 6.60 21.11 9.53 9.56
Net Debt to NOPAT		 0.00 4.10 12.02 6.13 7.19
Long-Term Debt to NOPAT		 0.00 4.97 15.69 7.19 6.76
Altman Z-Score		 0.00 0.00 0.00 2.10 2.11
Noncontrolling Interest Sharing Ratio		 0.00% 0.47% 0.27% 0.26% 0.32%
Liquidity Ratios		 - - - - -
Current Ratio		 0.00 0.97 1.14 1.05 0.81
Quick Ratio		 0.00 0.86 1.06 0.95 0.71
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -2,781 -4,836 213 476
Operating Cash Flow to CapEx		 282.26% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -60.59 -50.69 0.88 1.93
Operating Cash Flow to Interest Expense		 4.49 9.53 4.22 1.50 1.59
Operating Cash Flow Less CapEx to Interest Expense		 2.90 9.74 4.22 1.50 1.59
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.70 0.45 0.49 0.51
Accounts Receivable Turnover		 0.00 5.61 5.23 6.45 6.02
Inventory Turnover		 0.00 19.19 19.16 23.76 21.98
Fixed Asset Turnover		 0.00 7.43 7.90 11.10 10.77
Accounts Payable Turnover		 0.00 3.42 3.34 4.19 4.23
Days Sales Outstanding (DSO)		 0.00 65.05 69.73 56.59 60.59
Days Inventory Outstanding (DIO)		 0.00 19.02 19.05 15.36 16.61
Days Payable Outstanding (DPO)		 0.00 106.84 109.30 87.13 86.22
Cash Conversion Cycle (CCC)		 0.00 -22.77 -20.52 -15.18 -9.02
Capital & Investment Metrics		 - - - - -
Invested Capital		 0.00 3,160 8,297 8,700 8,745
Invested Capital Turnover		 0.00 2.53 0.78 0.81 0.78
Increase / (Decrease) in Invested Capital		 0.00 3,160 5,137 403 45
Enterprise Value (EV)		 0.00 0.00 0.00 17,937 16,540
Market Capitalization		 0.00 0.00 0.00 14,144 12,774
Book Value per Share		 $0.00 $0.00 $1.96 $2.06 $2.09
Tangible Book Value per Share		 $0.00 $0.00 ($1.54) ($1.50) ($1.44)
Total Capital		 0.00 4,209 11,282 11,077 10,276
Total Debt		 0.00 2,503 6,333 5,868 4,982
Total Long-Term Debt		 0.00 1,883 4,709 4,423 3,522
Net Debt		 0.00 1,555 3,607 3,776 3,749
Capital Expenditures (CapEx)		 169 -9.45 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -350 -517 -414 -312
Debt-free Net Working Capital (DFNWC)		 0.00 558 2,105 1,595 849
Net Working Capital (NWC)		 0.00 -62 481 150 -611
Net Nonoperating Expense (NNE)		 71 24 20 130 137
Net Nonoperating Obligations (NNO)		 0.00 1,454 3,348 3,490 3,451
Total Depreciation and Amortization (D&A)		 0.00 278 307 349 353
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -8.76% -11.52% -6.05% -4.58%
Debt-free Net Working Capital to Revenue		 0.00% 13.97% 46.93% 23.29% 12.47%
Net Working Capital to Revenue		 0.00% -1.56% 10.72% 2.20% -8.98%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.15 $0.15
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 2.52B 2.52B
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.15 $0.15
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 2.52B 2.52B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 2.52B 2.52B
Normalized Net Operating Profit after Tax (NOPAT)		 325 379 323 654 574
Normalized NOPAT Margin		 8.48% 9.50% 7.20% 9.55% 8.44%
Pre Tax Income Margin		 8.21% 10.99% 7.97% 9.17% 7.45%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 3.87 10.44 4.13 3.35 2.82
NOPAT to Interest Expense		 3.05 8.26 3.15 2.56 2.11
EBIT Less CapEx to Interest Expense		 2.28 10.65 4.13 3.35 2.82
NOPAT Less CapEx to Interest Expense		 1.46 8.46 3.15 2.56 2.11
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Rentokil Initial

No quarterly metrics and ratios for Rentokil Initial are available.

Frequently Asked Questions About Rentokil Initial's Financials

When does Rentokil Initial's fiscal year end?

According to the most recent income statement we have on file, Rentokil Initial's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Rentokil Initial's net income changed over the last 4 years?

Rentokil Initial's net income appears to be on an upward trend, with a most recent value of $384.39 million in 2024, rising from $254.02 million in 2020. The previous period was $485.51 million in 2023.

What is Rentokil Initial's operating income?
Rentokil Initial's total operating income in 2024 was $687.40 million, based on the following breakdown:
  • Total Gross Profit: $757.52 million
  • Total Operating Expenses: $70.12 million
How has Rentokil Initial revenue changed over the last 4 years?

Over the last 4 years, Rentokil Initial's total revenue changed from $3.83 billion in 2020 to $6.81 billion in 2024, a change of 77.8%.

How much debt does Rentokil Initial have?

Rentokil Initial's total liabilities were at $7.92 billion at the end of 2024, a 11.7% decrease from 2023, and a 91.7% increase since 2021.

How much cash does Rentokil Initial have?

In the past 3 years, Rentokil Initial's cash and equivalents has ranged from $901.80 million in 2021 to $2.62 billion in 2022, and is currently $1.16 billion as of their latest financial filing in 2024.

How has Rentokil Initial's book value per share changed over the last 4 years?

Over the last 4 years, Rentokil Initial's book value per share changed from 0.00 in 2020 to 2.09 in 2024, a change of 209.2%.


Related Companies

This page (OTC:RKLIF) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners
Feds Just Admitted It—They Can Take Your Cash
Here’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...
Priority Gold | Sponsored
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Crypto 101 Media | Sponsored
M.A.G.A. is Finished – This Could be even Better
You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...
Paradigm Press | Sponsored
The Exact July Date the AI Correction Will End?
AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...
Brownstone Research | Sponsored
This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...
Colonial Metals | Sponsored
Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...
Stansberry Research | Sponsored
Trump’s treachery
Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...
Porter & Company | Sponsored